IGC Pharma (IGC) Operating Expenses (2010 - 2025)

IGC Pharma (IGC) has reported Operating Expenses for 16 consecutive years, with $3.0 million the latest figure, recorded in Q3 2025.

• On a quarterly basis, Operating Expenses rose 53.12% year-over-year to $3.0 million in Q3 2025; TTM through Sep 2025 was $10.2 million, a 1.57% increase from a year earlier, with the FY2026 full-year figure at $2.5 million, down 69.01% from the prior year.
• Operating Expenses was $3.0 million for Q3 2025 at IGC Pharma, down from $3.6 million in the prior quarter.
• Over five years, Operating Expenses peaked at $6.6 million in Q1 2022 and troughed at $1.6 million in Q1 2025.
• A 5-year average of $2.9 million and a median of $2.6 million in 2022 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses soared 157.7% in 2021 and tumbled 42.82% in 2024, its largest moves.
• Over 5 years, Operating Expenses stood at $2.4 million in 2021, then fell by 2.74% to $2.4 million in 2022, then jumped by 31.55% to $3.1 million in 2023, then plunged by 36.7% to $2.0 million in 2024, then soared by 51.26% to $3.0 million in 2025.
• The last three Operating Expenses figures came in at $3.0 million (Q3 2025), $3.6 million (Q2 2025), and $1.6 million (Q1 2025), per Business Quant data.